WO1990004389A1 - Use of resiniferatoxin and analogues thereof to cause sensory afferent c-fiber and thermoregulatory desensitization - Google Patents

Use of resiniferatoxin and analogues thereof to cause sensory afferent c-fiber and thermoregulatory desensitization Download PDF

Info

Publication number
WO1990004389A1
WO1990004389A1 PCT/US1989/004769 US8904769W WO9004389A1 WO 1990004389 A1 WO1990004389 A1 WO 1990004389A1 US 8904769 W US8904769 W US 8904769W WO 9004389 A1 WO9004389 A1 WO 9004389A1
Authority
WO
WIPO (PCT)
Prior art keywords
rtx
capsaicin
desensitization
vol
pain
Prior art date
Application number
PCT/US1989/004769
Other languages
French (fr)
Inventor
Peter M. Blumberg
Original Assignee
The United States Of America, Represented By The Secretary, United States Department Of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, Represented By The Secretary, United States Department Of Commerce filed Critical The United States Of America, Represented By The Secretary, United States Department Of Commerce
Priority to DE89912770T priority Critical patent/DE68910834T2/en
Priority to AT89912770T priority patent/ATE97320T1/en
Priority to JP2500630A priority patent/JPH0729919B2/en
Publication of WO1990004389A1 publication Critical patent/WO1990004389A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to the use of resiniferatoxin to desensitize a subject animal to neuro ⁇ genic inflammation, to chemically and thermally induced pain, to responses involving sensory afferent pathways sensitive to capsaicin (e.g. sensory afferent C-Fibers) and to responses involving the hypothalamic temperature control region.
  • resiniferatoxin to desensitize a subject animal to neuro ⁇ genic inflammation, to chemically and thermally induced pain, to responses involving sensory afferent pathways sensitive to capsaicin (e.g. sensory afferent C-Fibers) and to responses involving the hypothalamic temperature control region.
  • the phorbol esters together with the struc ⁇ turally related ingenol and resiniferonol esters, are diterpene derivatives from plants of the families Euphorbiaceae and Thymeleaceae (Evans, F.J. and Taylor, S.E. (1983) Fortshr. d. Che . organ. Naturst., Vol. 44, pp. 1-99; Hecker, E. (1978) In Carcinogenesis, Mechanisms of Tumor Promotion and Cocarcinogenesis (T.J. Slaga, A. Sivak and R.K. Boutwell, Eds.), Vol. 2, pp. 11-48, Raven Press, New York).
  • the phorbol esters have been the objects of intense research interest due to their tumor promoting activity (Hecker, E. (1968) Cancer Res. , Vol. 28, pp. 2238-2349). More recently, the description of the role of the phorbol esters as modulators of protein kinase have been studied (Ashendel, C.L. (1985) Biochim. Biophvs. Acta, Vol. 822, pp. 219-242; Blumberg, P.M. (1988) Cancer Res. , Vol. 48, pp. 1-8). These compounds are also potent irritants, and their isolation from natural sources has been guided by the activity of organic extracts of the plants in a mouse ear reddening assay (Hecker, E., Im ich, H.
  • RTX differs from the tumor promoting resiniferonol derivatives in that it is esterified at this position. Structure-activity analysis indicates that this substituent, 4-hydroxy-3-methoxy-phenylacetate, plays an essential role in determining activity. (Adolph, . , Sorg, B., Hergenhahn, M. and Hecker, E. (1982) J. Nat. Prod., Vol. 45, pp. 347-354; Schmidt, R.J.
  • Capsaicin the irritant component in fruit of various species of Capsicum, also possesses a 4-hydroxy- 3-methoxyphenyl substituent which is critical for activity (Szolcsanyi, J. and Jancso-Gabor. A, (1975), Arzneim-Forsch, Vol. 25, pp. 1877-1881).
  • capsaicin One well documented action of capsaicin is to produce a dramatic fall in body temperature (Jancso- Gabor, A., Szolcsanyi, J. and Jancso, N. (1970), J. Physiol, Vol. 208, pp. 449-459; Szikszay, M. , Obal, F. Jr., and Obal, F. (1982) Naunyn-Schmiedeberg 's Arch. Pharmacol, Vol. 320, pp. 97-100). The inventors have explored possible homology between these two classes of irritant compounds to determine if RTX has a role in thermoregulation and to compare these effects with those of capsaicin.
  • the present invention relates to a method for desensitizing a subject animal which comprises admini- stering to the subject a therapeutically effective desensitizing amount of resiniferatoxin for desensitizing the subject animal to neurogenic inflammation, to chemically and thermally induced pain, to responses involving sensory afferent pathways sensitive to capsaicin (e.g. sensory afferent C-Fibers) and to responses involving the hypothalamic temperature control region, and a pharmaceutically acceptable carrier there ⁇ for.
  • the resiniferatoxin may be admini ⁇ stered topically, subcutaneously, intraperitoneally or intravenously.
  • Figure 2 shows the induction of hypothermia in rats by RTX or capsaicin.
  • Figure 3 shows the body temperature of rats as a function of time after the administration of RTX.
  • Figure 4 shows the dose dependence of desensi- tization to hypothermic action and Evans blue extravasa ⁇ tion.
  • Figure 5 shows the dose dependence of Evans blue extravasation induced by topical RTX or capsaicin.
  • Figure 6 shows the dose dependence of eye wiping in rats in response to instillation of RTX or capsaicin.
  • Figure 7 shows the water content of the hind paw skin of rats after RTX treatment.
  • Figure 8 shows the body temperatures of the mice.
  • Figure 9 shows the dose response curves for change in body temperature in mice.
  • Figure 10 shows the effect of repeated treat- ment with RTX or capsaicin on body temperature in mice.
  • Resiniferatoxin is a naturally occurring diterpene, structurally related to the phorbol esters, and was identified in the latex of 3 species of Euphorbia (j ⁇ . resinifera. ⁇ . poissonii, and E ⁇ . inispina) (Hergenhahn et al (1975) Tetrahedron Lett. 19, 1595-1598 and Schmidt et al (1976) Phytochemistry 15, 1778-1779). RTX was isolated on the basis of extraordinary activity in the mouse ear reddening assay (Hergenhahn et al (1975) Tetrahedron Lett.
  • phorbol 12-myristate 13- acetate (Hecker, E. (1978) in Carcinogenesis, Mechanism of Tumor Promotion and Cocarcinogenesis, eds. Slaga, T.J. , Sivak, A. and Boutwell, C.K. (Raven Press, New York), Vol. 2, pp. 11-48 and Adolph et al (1982) J. Nat. Prod. 45, 347-354). Characterization of RTX strong ⁇ ly suggested that its primary target was distinct from that of the phorbol esters.
  • RTX Unlike the persistent inflammation induced by the phorbol esters, the ear reddening induced by RTX was transient (Adolph et al (1982) J. Nat. Prod. 45, 347-354, Schmidt et al (1979) Inflammation 3, 273-280 and Hergenhahn et al (1982) J. Cancer Res. Clin. Oncol. 104, 31-39). RTX was not tumor promoting (zur Hausen et al (1979) Proc. Natl. Acad. Sci. USA 76, 782-785); RTX did not induce typical phorbol ester responses in cultured cell systems (zur Hausen et al (1979) Proc. Natl. Acad. Sci.
  • a free 20-hydroxyl group is critical for phorbol ester activity (Hecker, E. (1978) in Carcinogenesis, Mechanism of Tumor Promotion and Cocarcinogenesis, eds. Slaga, T.J., Sivak, A. and Boutwell, C.K. (Raven Press, New York), Vol. 2, pp. 11- 48).
  • RTX in contrast, is esterified at this position with 4-hydroxy-3-methoxyphenylacetate, and this sub- stituent has been shown to be essential for its unusual irritant activity (Adolph et al (1982) J. Nat. Prod. 45, 347-354 and Schmidt et al (1979) Inflammation 3, 273- 280).
  • capsaicin the major pungent constituent of red pepper and other plants of the genus Capsicum (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55 and Szolcsanyi et al (1975) Arzneim-Forsch. (Drug Res.) 25, 1877-1881) (See Figure 1).
  • Structure-activity analysis of capsaicin congeners indicates that an ester linkage such as is found in RTX is adequately tolerated in place of the amide linkage present in the opposite orientation in capsaicin.
  • Capsaicin causes diverse physiological effects, of which pain, neurogenic edema, and hypothermia are prominent examples (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55, Szolcsanyi et al (1975) Arzneim-Forsch. (Drug Res.) 25, 1877-1881 and Buck et al (1986) Pharmacol. Rev. 38, 179- 226). Acute response is followed by long-lasting desensitization. The postulated cellular mechanism is by transient activation followed by desensitization and, under some conditions, degeneration of C-fiber sensory afferent neurons (Jancso, N.
  • RTX and capsaicin have confirmed the possible homology of RTX and capsaicin (i.e. both compounds pro ⁇ quizzed a dramatic fall in body temperature in mice followed by cross-tolerance (deVries et al (1988) sub ⁇ mitted, Life Sciences) and have now compared the potencies and xn_ vivo activities of RTX and capsaicin in detail, as discussed hereinbelow.
  • RTX qualitatively resembles capsaicin in its activity, but differs quantitatively in potency (i.e. 10' * ' - 10 4 fold more potent) and in relative spectrum of actions.
  • Resiniferatoxin thus causes desensitization to neurogenic inflammation, to chemically and thermally induced pain, and to responses involving sensory afferent pathways including C-fibers and the hypothalamic temperature control region.
  • the induced desensitization may have application in arthritis, asthma, allergic responses, fever, pain associated with cancer or Herpes virus infection, and in biological pro- Waits mediated by substance P or other neuropeptides depleted by capsaicin treatment.
  • resiniferatoxin has similar effects to capsaicin, but differs in its much greater potency - up to 10 , which should remarkably reduce side effects and permit easier application (i.e. smaller volume or absorption through inefficient routes) .
  • RTX also shows a somewhat different spectrum of action, enabling greater desensitization at a given level of systemic toxicity and greater desensitization relative to acute induction of pain.
  • RTX desensitization by resiniferatoxin can be activated by topical, intravenous, intra- peritoneal, and subcutaneous administration.
  • RTX may be administered to an animal such as a mammal (e.g. mouse, r t or human) .
  • capsaicin exerts its actions on all mammals examined, but not on birds and lower vertebrates (Monsereenusorn et al (1982) CRC Crit. Rev. Toxicol. 10, 321-339). Based on the resemblances in the activities of capsaicin and resini ⁇ feratoxin documented in this application, we extrapolate that the effects of resiniferatoxin are not limited to rats and mice but extend to man as well.
  • Resiniferatoxin an extremely irritant diterpene present in several members of the genus Euphorbia, produced an 8°C decrease in the rectal temper- ature of mice with an effective dose in the range of 2-20 ⁇ g/kg.
  • the structurally related natural product capsaicin produced a similar magnitude of fall in body temperature albeit with 1000-fold lower potency. Tolerance to the hypothermic effects of both drugs developed readily and cross-tolerance between drugs was observed.
  • the extreme potency of resiniferatoxin should facilitate biochemical analysis of the mechanism of action of this class of compounds.
  • RTX was remarkable for its potency in the mouse ear reddening assay. Its 50% effective dose, 1.6 x 10 " moles/ear, indicated a 1000-fold greater potency than that of the most active of the typical phorbol esters, phorbol 12-myristate 13-acetate. (Adolf, W. , Sorg., B., Hergenhahn, M. and Hecker, E. (1982) J_. Nat. Prod. , Vol. 45, pp. 347-354).
  • RTX is not tumor promoting and is much less potent than typical phorbol esters at eliciting responses in a range of cultured cells.
  • RTX does not compete for phorbol ester binding sites on protein kinase C.
  • RTX the active ingredient of the present invention
  • RTX can be dissolved in oils, propyleneglycol or other solvents commonly used to pre ⁇ pare injectable solutions.
  • Suitable carriers include physiological saline, polyethylene glycol, ethanol, sesame oil, cremophor and isopropyl myristate.
  • RTX can be formulated as an ointment or cream.
  • the compounds of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
  • the compounds of the present invention may be formulated into preparations for injections by dis- solving, suspending or emulsifying them in aqueous solvents such as normal saline. Dextrose 5%, or non- aqueous solvent, such as vegetable oil, synthetic ali ⁇ phatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspend ⁇ ing agents, emulsifying agents, stabilizers and preserva ⁇ tives.
  • the compounds of the invention may be combined with other compounds having the desired effect.
  • the desirable dose of the compounds of the present invention varies with the subject, drug form, method and period of administration. However, in order to obtain desirable effects, generally it is recommended to administer 0.1 x 10 ⁇ 3 to 5 x 10" 2 mg/kg, preferably 0.1 x 10 ⁇ 3 to 5 x 10 ⁇ 3 mg/kg, body weight of the com ⁇ pounds of the present invention for single application, or less upon multiple application. In terms of composi ⁇ tion, compounds should be present between .0001 to 10% by weight, preferably .0001 to 1% by weight.
  • RTX acts as an ultrapotent capsaicin analog and may distinguish between subclasses of capsaicin response.
  • Sprague-Dawley rats females, 250-300 g are purchased from the Zivic-Miller Laboratories, (Zelienople, PA). Animals are allowed access to food and water ad libitum through the course of the experiments. The numbers of animals used in different experimental groups are indicated in the legends to 1-3 tables and Figures 1-10.
  • RTX (MW 628) is obtained from Chemicals for Cancer Research, Inc. (Chanhassen, MN), and Capsaicin (MW 305) from Polysciences (Warrington, PA). The com ⁇ pounds are administered in 10% ethanol/ 10% Tween-80/ 80% physiological saline solution unless otherwise indicated.
  • Pain-Inducing Potency Acute pain-inducing potency of the compounds is assessed as described by Jancso et al (Jancso et al (1961) Acta Physiol. Acad. Sci. Hung. 19, 113-131), which is herein incorporated by reference. Briefly, solutions at ten-fold increasing concentrations of compound in physiological saline are dropped into the eyes of rats and the number of protective movements (eye-wipings with the foreleg) is determined. To minimize the irritant being rinsed out by lacrimation, the instillation is repeated once. The solution by itself induced no wipings.
  • the extent of edema is measured by treating the hind paw with the irritant or solvent. At the indicated time (e.g. 30 minutes) the animal is killed, 1 cm diameter skin punches are removed and quickly weighed, and after drying for 24 hours at 50°C the skin punches are reweighed. The difference in the water content between irritant-and solvent-treated animals represents the extent of edema (Fischer et al (1988) Cancer Res. 48, 659-664).
  • RTX is injected subcutaneously and 4 hours later capsaicin is instilled into the eye.
  • Antinociceptive effect against chronic pain is tested by the method of Dubuisson et al (1977) Pain 4, 161-174.
  • 5% formalin solution is injected under the plantar surface of the right forepaw 4 hours after topical RTX or capsaicin administration.
  • Behavior of animals is scored as described in Dubuisson et al (1977) Pain 4, 161-174 during an observation period of 60 minutes.
  • Heat nociception is examined in the tail- immersion test at 50°C (D'Amour et al (1941) J. Pharmacol. Exp. Ther.
  • Desensitization against the inflammatory response is determined by measuring extravasated Evan's blue after a high paw has been painted with xylene, an effective inducer of neurogenic inflammation (Jancso et al (1967) Br. J. Pharmacol. Chemother. 31, 138-151). Desensitiza ⁇ tion is also determined by measuring extravasated Evan's blue after dextran is injected under the hind paw skin (25 ug in a volume of 50 ul); dextran releases vasoactive substances without causing neurogenic inflammation (Jancso et al (1967) Br. J. Pharmacol. Chemother. 31, 138-151) . Results
  • RTX like capsaicin, causes a 2-3°C drop in rectal temperature 1 hour after treatment of rats maintained at 20°C (See Figure 2).
  • the ED 50 for RTX is 3 x 10 g/kg, compared to an ED ⁇ Q for capsaicin of 2 x 10 ⁇ 3 g/kg.
  • Capsaicin desensitized rats display an inability to adapt to heat stress (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55 and Virus et al (1979) Life Sci. 25, 1273- 1284). If subjected to elevated ambient temperature (38°C), RTX-desensitized rats show a steady rise in body temperature, ultimately leading to collapse, in contrast to control animals (See Figure 3B) .
  • Desensitization with capsaicin can be achieved either by means of a single large dose or of repeated incremental doses (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55 and Buck et al (1986) Pharmacol. Rev. 38, 179-226).
  • the former procedure is more convenient for quantitation and com ⁇ parison. Therefore, the dose dependency was determined for desensitization to RTX-induced hypothermia following pretreatment with a single, subcutaneous injection of RTX (See Figure 4) .
  • the dose response curve was extremely steep and yielded an ED 5Q of 5 X 10 ⁇ " g/kg. This value is approximately an order of magnitude greater than the EDc jQ for the direct hypothermic effect, but similar to that which gives a maximal response.
  • Induction of neurogenic inflammation is a second prominent feature of the capsaicin response (Jancso et al (1967) Br. J. Pharmacol. Chemother. 31, 138-151, Virus et al (1979) Life Sci. 25, 1273-1284 and Monsereenusorn et al (1982) CRC Crit. Rev. Toxicol. 10, 321-339). Inflammation was quantified by measuring extravasation of Evan's blue dye. Like capsaicin, RTX applied topically to the hind paw of rats causes dramatic extravasation. The ED ⁇ Q for topical administration of RTX is 3 x 10 g/paw, compared to an ED ⁇ Q for capsaicin of 3 x 10 ⁇ 2 g/paw (See Figure 5).
  • the kinetics of edemas formation are determined from the water content of the hind paw skin as a function of time. No edema formation is observed up to 30 minutes; the water content reaches its peak at 90 minutes; and the edema disappears by 4 hours (See Figure 7).
  • the solvent acetone by itself did not have any effect.
  • the left saphenous nerve is cut 3 days before the experiment. Irritant is applied topically in 50 ul acetone on both hind paws; the intact paw serves as a positive control. Values are the mean +_ SEM standard error of the mean for 10 - 14 animals in 2 experiments.
  • Capsaicin treatment is followed by desensitiza ⁇ tion to neurogenic inflammation (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55, Buck et al (1986) Pha acol. Rev. 38, 179-226, Virus et al (1979) Life Sci. 25, 1273-1284 and Monsereenusorn et al (1982) CRC Crit. Rev. Toxicol. 10, 321-339). Injection of RTX subcutaneously likewise pre ⁇ vents Evan's blue extravasation upon challenge 4 hours later with either RTX or capsaicin as shown in Table 2 below. RTX pretreatment similarly blocks response to xylene, another potent neurogenic irritant (Jancso et al (1967) Br. J. Pharmacol. Chemother. 31, 138-151), but has - 16 -
  • RTX 50 ug/paw
  • dextran 25 ug in 50 ul saline
  • RTX 300 ug/kg is injected under the back skin. Controls are injected with vehicle alone. 4 hours later xylene, capsaicin, or RTX is painted on the skin of the hind paw or dextran is injected under the skin. Evan's blue extravasation is determined 10 minutes after xylene or dextran treatment and 30 minutes after capsaicin or RTX treatment. Values are the mean for 8-10 animals in 2 experiments.
  • RTX The desensitization induced by subcutaneously injection of RTX is rapidly expressed and of long dura ⁇ tion. Inhibition of neurogenic inflammation is greater than 70% by 1 hour and achieves a level plateau by 4 hours which is maintained over the next 4 days. Responsiveness only partially returns by 7 days after treatment.
  • RTX is 5 x 10" 6 g/kg (See Figure 4).
  • ED 50 for inhibition of xylene-induced Evan's blue extravasation by subcutaneous injection for capsaicin is 10 g/kg.
  • capsaicin potently stimulates chemogenic pain receptors (Jancso, N. (1968) in Pharmacology of pain
  • the difference in potency is much less than the 10 -10 -fold difference observed for the hypothermic and inflammatory effects.
  • a latency period of 5-10 seconds is observed for RTX treatment compared to an immediate response upon capsaicin instillation, and the duration of the response is longer. Extension of the dose response curves for the eye wiping response to higher levels is not carried out so as to avoid undue pain.
  • RTX Injection of RTX subcutaneously causes desensi ⁇ tization of the eye wiping response to capsaicin.
  • the ED5 Q for RTX is 1 x I0 ⁇ 7 g/kg, a dose significantly less than that for desensitization to the hypothermic and inflammatory effects. This difference is confirmed in animals treated with RTX at 1 x 10 g/kg and assessed for both the eye wiping response and Evan's blue extrava ⁇ sation.
  • RTX desensitization to chemical and thermal nociception is also examined in two other standard assays such as (i) response to formalin injection into the fore ⁇ paw (Dubuisson et al (1977) Pain 4, 161-174 and Hayes et al (1981) Neuropharmacol 20, 505-511) and (ii) tail immersion into 50°C water (D'Amour et al (1941) J. Pharmacol. Exp. Ther. 72, 74-79 and Gamse, R. (1982) Naunyn-Schmiedeberg's Arch. Pharmacol. 320, 205-216). RTX blocks nociception in both cases and does so with greater potency than does capsaicin as shown in Table 3 below. TABLE 3 Effect of RTX Pretreatment on Sensory Functions Pretreatment a Pain-inde Latency time c
  • RTX 100 ug/paw 0.2 42.0 +_ 9.3 capsaicin, 3 mg/paw 0.2 19.4 +_ 8.1 a Capsaicin and RTX at the indicated doses are injected under the plantar surface of the forepaw in a volume of 50 ul.
  • RTX induces each of the three characteristic acute physiological responses to capsaicin which are examined - hypothermia, neurogenic inflamma ⁇ tion, and pain.
  • the acute response to RTX is followed by desensitization, a typical feature of capsaicin but not of unrelated irritants.
  • the RTX-desensitized animals moreover, displays cross-tolerance to capsaicin.
  • RTX mimicks capsaicin in its quali ⁇ tative action, quantitatively it differs drammatically in potency. RTX is much more potent than capsaicin for induction of hypothermia (7 x 10 -fold, administered subcutaneously) , for induction of neurogenic inflammation (1 x 10 3 -fold, applied topically), and for desensitiza ⁇ tion of neurogenic inflammation (2 x 10 -fold, admini ⁇ stered subcutaneously) . In studies in the mouse, (Example 2 below) ⁇ RTX is also found to be 2 x 10 -fold more potent for induction of hypothermia.
  • RTX In addition to being more potent than capsaicin as demonstrated by the above assays, RTX also displays a different spectrum of action.
  • the potency of RTX in the eye wiping assay a measure of acute pain, is within a factor of 2 of that of capsaicin, in contrast to the 10 - 10 5 -fold difference described above.
  • a single dose of RTX affords complete desensitization, whereas the maximum tolerated dose of capsaicin causes only partial desensitization. This qualitative difference may reflect different rela ⁇ tive toxicities upon subcutaneous administration.
  • RTX The maximum tolerated dose of RTX is approximately 100-fold its EDt- jQ for desensitization of neurogenic inflammation, whereas the ED5 Q for capsaicin is the maximum tolerated dose.
  • capsaicin causes both acute irritation and long lasting desensiti ⁇ zation, zingerone, the pungent ingredient in ginger, lacks desensitizing activity (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55). It has been suggested that the acylamide linkage, which is present in capsaicin but missing in zingerone, might be essential for desensitization (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55). The high desensi ⁇ tizing potency of RTX argues against this suggestion.
  • RTX represents a powerful new tool for probing mechanisms of pain, neurogenic inflammation, and thermo- regulation. Its high potency should facilitate receptor analysis; its structural relationship to the phorbol- related diterpenes affords a new family of derivatives to define the capsaicin pharmacophor . Given the potential therapeutic implications of C-fiber desensitization, the unique spectrum of action of RTX is of particular interest.
  • Example 1 The figures of Example 1 are discussed in greater detail hereinbelow.
  • Figure 1 shows a comparison of the structures of capsaicin and resiniferatoxin.
  • Figure 2 shows the induction of hypothermia in rats by RTX or capsaicin.
  • the fall in rectal temperature is measured 1 hour after the subcutaneous injection of RTX ( • ) or capsaicin (o) at the indicated doses. Points represent the mean for 10 animals in 2 experi ⁇ ments.
  • Figure 3 shows the body temperature of the rats as a function of time after administration of RTX.
  • Figure 4 shows the dose dependence of desensi- tization to hypothermic action and Evans blue extravasa ⁇ tion.
  • Extravasation is induced by xylene (50 ul/paw) 4 hours after RTX ( A ) or capsaicin ( ⁇ ) is in ected sub- cutaneously at the indicated doses. Values are the mean +_ SEM for 8-12 animals in 3 experiments.
  • Q represents xylene-induced Evans blue extravasation in vehicle con ⁇ trols.
  • Hypothermia is induced by injection of 100 g/kg RTX, a dose providing a maximal response, 12 hours after RTX pretreatment ( • ) at the indicated doses. The time interval is chosen to avoid any interference between hypothermia produced by the pretreatment and the test dosage. Values are the mean for 8-10 animals in 2 experiments.
  • Figure 5 shows the dose dependence of Evans blue extravasation induced by topical RTX or capsaicin.
  • RTX •
  • capsaicin o
  • Figure 6 shows the dose dependence of eye wiping in response to instillation of RTX or capsaicin.
  • RTX ( • ) or capsaicin ( o ) solutions at the indicated concentrations is instilled into the eyes of rats. Each value is the mean +_ SEM for 12 animals in 3 experiments.
  • Figure 7 shows the water content of the hind paw skin of rats after RTX treatment.
  • Resiniferatoxin 50 ug
  • Body temperature of the mice is determined essentially as described by Obal and coworkers. (Szikszay, M. , Obal, F. Jr. and Obal, F. (1982) Naunyn- Schmiedeberq's Arch. Pharmacol., Vol. 320, pp. 97-100).
  • mice From 10-36 female CD-I mice, 25-30 g, are habituated prior to treatment to both the experimental room (22-23°C) and to the small-animal temperature probe (Cole-Parmer, Chicago, IL) which is introduced rectally to a depth of 2.5 cm.
  • Drugs are prepared in 10% ethanol/10% Tween-80/80% phosphate buffered saline and administered in volumes of less than 0.1 ml at the indi- cated doses of 0.2-40 ug/kg of resiniferatoxin or 2-15 mg/kg of capsaicin. Animals are allowed free access to food and water through the course of the experiments.
  • Resiniferatoxin (M.W. 628) was obtained from Chemicals for Cancer Research (Chanhassen, MN) and capsaicin (M.W. 305) from Polysciences (Warrington, PA). Results
  • Capsaicin (15 mg/kg) produces a profound drop in the body (rectal) temperature of mice upon subcu ⁇ taneous injection as shown in Figure 8. The effect is maximal at 1 hour and returns to baseline by 3 hours.
  • RTX (20 g/kg) causes a comparable drop in body temper ⁇ ature. However, the duration of action of RTX is several-fold longer.
  • Relative potencies of capsaicin and RTX are determined measuring the drop in body temperature 1 hour after treatment. RTX has a 50% effective dose of 3 g/kg while capsaicin displays a 50% effective dose of 7 mg/kg as shown in Figure 9.
  • the drop in body temperature induced by both agents at maximally tolerated doses is approximately 8°C.
  • RTX and capsaicin share a capacity to dramati- cally depress the rectal temperature of mice. This effect may in part be due to the irritant/vasodilatory action of both compounds, contributing to enhanced heat loss.
  • capsaicin to dis ⁇ creet areas of the brain has strongly argued for a central site of action of this compound on thermoregula ⁇ tion (Monsereenusorn, Y., Kongsamut, S. and Pezalla, P.D. (1982) CRC Crit. Rev. Toxicol., Vol. 10, pp. 321-339).
  • the rapidity and degree of hypothermia induced by RTX may also argue for a central site of action.
  • Capsaicin has been reported to potently inter ⁇ act with the hepatic microsomal drug-metabolizing system and to irreversibly bind to microsomal proteins (Miller, M.S., Brendel, K., Burks, T.F. and Sipes, I.G. (1983) Biochem. Pharmacol. , Vol. 32, pp. 547-551). Suscepti ⁇ bility to biotransformation may explain the relatively short duration of action of capsaicin and its lack of potency when administered intraperitoneally.
  • 97-100 is indicative of some form of central response to the hypothermic stress and may contribute to the tolerance and cross-tolerance phenomena observed.
  • the remarkable potency of RTX as both an irritant and hypothermic agent indicates its potential as a pharmacological tool.
  • Elucidation of the mechanism of action of capsaicin has been hampered by the relatively modest potency of this drug. Comparisons between the actions of RTX and capsaicin in various other paradigms may prove fruitful in delineating the mechanisms of these interesting natural products.
  • Figure 8 shows the body temperature in mice as a function of time after administration at time "0" of vehicle ( £ ), 20 /jg/kg RTX (•) or 15 mg/kg capsaicin ( ) subcutaneously. Each data point is the mean value from 4 animals +_ s.e.m..
  • Figure 9 shows the dose response curves for change in body temperatures 1 hour after treatment with RTX (•) or capsaicin ( - ) . RTX was administered i.p. (intraperitoneally); capsaicin was administered s.c. Each point represents the difference between mean values pre-and post-treatment for 2-4 animals in five individual experiments.
  • Figure 10 shows the effect of repeated treat ⁇ ments with RTX or capsaicin on body temperature. Values represent the mean and s.e.m. of values obtained from 4 animals injected s.c. Body temperatures are measured before ( o / O , ) and one hour after ( V , • / ⁇ ) treatment. Vehicle control ( D )• Treatment with
  • RTX (0, o) at a rate of 20 /jg/kg on days 1 and 2 and 40 g/kg on days 3 and 4.
  • cross-tolerance is examined by injection of 15 mg/kg capsaicin.
  • On day 5 cross- tolerance is examined by injection of 20 g/kg RTX.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Purification Treatments By Anaerobic Or Anaerobic And Aerobic Bacteria Or Animals (AREA)

Abstract

The present invention relates to a method for desensitizing a subject animal, which comprises administering to the subject animal a therapeutically effective desensitizing amount of resiniferatoxin for desensitizing the subject animal to neurogenic inflammation, to chemically and thermally induced pain and to responses involving sensory afferent pathways sensitive to capsaicin and to responses involving the hypothalamic temperature control region, and a pharmaceutically acceptable carrier therefor.

Description

USE OF RESINIFERATOXIN AND ANALOGUES THEREOF TO CAUSE SENSORY AFFERENT C-FIBER AND THERMOREGULATORY DESENSITIZATION
FIELD OF THE INVENTION The present invention relates to the use of resiniferatoxin to desensitize a subject animal to neuro¬ genic inflammation, to chemically and thermally induced pain, to responses involving sensory afferent pathways sensitive to capsaicin (e.g. sensory afferent C-Fibers) and to responses involving the hypothalamic temperature control region.
BACKGROUND OF THE INVENTION The phorbol esters, together with the struc¬ turally related ingenol and resiniferonol esters, are diterpene derivatives from plants of the families Euphorbiaceae and Thymeleaceae (Evans, F.J. and Taylor, S.E. (1983) Fortshr. d. Che . organ. Naturst., Vol. 44, pp. 1-99; Hecker, E. (1978) In Carcinogenesis, Mechanisms of Tumor Promotion and Cocarcinogenesis (T.J. Slaga, A. Sivak and R.K. Boutwell, Eds.), Vol. 2, pp. 11-48, Raven Press, New York). The phorbol esters have been the objects of intense research interest due to their tumor promoting activity (Hecker, E. (1968) Cancer Res. , Vol. 28, pp. 2238-2349). More recently, the description of the role of the phorbol esters as modulators of protein kinase have been studied (Ashendel, C.L. (1985) Biochim. Biophvs. Acta, Vol. 822, pp. 219-242; Blumberg, P.M. (1988) Cancer Res. , Vol. 48, pp. 1-8). These compounds are also potent irritants, and their isolation from natural sources has been guided by the activity of organic extracts of the plants in a mouse ear reddening assay (Hecker, E., Im ich, H. , Bresch, H. and Schairer, H.-U. (1966) Z. Krebsforsch, Vol. 68, pp. 366-374). Resiniferatoxin (RTX), a resiniferonol ester, was iso- lated from Euphoribia resinifera, E. poissonii and E. unispina on the basis of this activity (Hergenhahn, M. , Adolph, W. and Hecker, E. (1975) Tet. Lett. Vol. 19, pp. 1595-1598; Evans, F.J. and Schmidt, R.J. (1976) Phytochemistry, Vol. 15, pp. 333-335).
For the phorbol esters, esterification of the exocyclic hydroxyl at C20 causes marked loss of activity (Hecker, E. (1978) Carcinogenesis, Mechanisms of Tumor Promotion and Cocarcinoqenesis, Vol. 2, pp. 11-48, Raven Press, New York). RTX differs from the tumor promoting resiniferonol derivatives in that it is esterified at this position. Structure-activity analysis indicates that this substituent, 4-hydroxy-3-methoxy-phenylacetate, plays an essential role in determining activity. (Adolph, . , Sorg, B., Hergenhahn, M. and Hecker, E. (1982) J. Nat. Prod., Vol. 45, pp. 347-354; Schmidt, R.J. and Evans, F.J. (1979) Inflammation, Vol. 3, pp. 273- 280). Capsaicin, the irritant component in fruit of various species of Capsicum, also possesses a 4-hydroxy- 3-methoxyphenyl substituent which is critical for activity (Szolcsanyi, J. and Jancso-Gabor. A, (1975), Arzneim-Forsch, Vol. 25, pp. 1877-1881).
One well documented action of capsaicin is to produce a dramatic fall in body temperature (Jancso- Gabor, A., Szolcsanyi, J. and Jancso, N. (1970), J. Physiol, Vol. 208, pp. 449-459; Szikszay, M. , Obal, F. Jr., and Obal, F. (1982) Naunyn-Schmiedeberg 's Arch. Pharmacol, Vol. 320, pp. 97-100). The inventors have explored possible homology between these two classes of irritant compounds to determine if RTX has a role in thermoregulation and to compare these effects with those of capsaicin.
U.S. Patent 4,716,179 by Hecker et al discloses the use of a non-irritating or slightly irritating and/or tumor promoting diterpene alcohol and of derivatives thereof as antineoplastic preparations. Resinferatoxin was found to have neither a curative nor a significant tumor-inhibiting effect in carcinomas. SUMMARY OF THE INVENTION
The present invention relates to a method for desensitizing a subject animal which comprises admini- stering to the subject a therapeutically effective desensitizing amount of resiniferatoxin for desensitizing the subject animal to neurogenic inflammation, to chemically and thermally induced pain, to responses involving sensory afferent pathways sensitive to capsaicin (e.g. sensory afferent C-Fibers) and to responses involving the hypothalamic temperature control region, and a pharmaceutically acceptable carrier there¬ for. Furthermore, the resiniferatoxin may be admini¬ stered topically, subcutaneously, intraperitoneally or intravenously.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 compares the structures of capsaicin and resiniferatoxin.
Figure 2 shows the induction of hypothermia in rats by RTX or capsaicin.
Figure 3 shows the body temperature of rats as a function of time after the administration of RTX. Figure 4 shows the dose dependence of desensi- tization to hypothermic action and Evans blue extravasa¬ tion.
Figure 5 shows the dose dependence of Evans blue extravasation induced by topical RTX or capsaicin. Figure 6 shows the dose dependence of eye wiping in rats in response to instillation of RTX or capsaicin.
Figure 7 shows the water content of the hind paw skin of rats after RTX treatment. Figure 8 shows the body temperatures of the mice.
Figure 9 shows the dose response curves for change in body temperature in mice.
Figure 10 shows the effect of repeated treat- ment with RTX or capsaicin on body temperature in mice.
DETAILED DESCRIPTION OF THE INVENTION Resiniferatoxin (RTX) is a naturally occurring diterpene, structurally related to the phorbol esters, and was identified in the latex of 3 species of Euphorbia (j^. resinifera. ^. poissonii, and E^. inispina) (Hergenhahn et al (1975) Tetrahedron Lett. 19, 1595-1598 and Schmidt et al (1976) Phytochemistry 15, 1778-1779). RTX was isolated on the basis of extraordinary activity in the mouse ear reddening assay (Hergenhahn et al (1975) Tetrahedron Lett. 19, 1595-1598), in which it exhibited 3 orders of magnitude greater potency than the most potent of the typical phorbol esters, phorbol 12-myristate 13- acetate (PMA) (Hecker, E. (1978) in Carcinogenesis, Mechanism of Tumor Promotion and Cocarcinogenesis, eds. Slaga, T.J. , Sivak, A. and Boutwell, C.K. (Raven Press, New York), Vol. 2, pp. 11-48 and Adolph et al (1982) J. Nat. Prod. 45, 347-354). Characterization of RTX strong¬ ly suggested that its primary target was distinct from that of the phorbol esters. Unlike the persistent inflammation induced by the phorbol esters, the ear reddening induced by RTX was transient (Adolph et al (1982) J. Nat. Prod. 45, 347-354, Schmidt et al (1979) Inflammation 3, 273-280 and Hergenhahn et al (1982) J. Cancer Res. Clin. Oncol. 104, 31-39). RTX was not tumor promoting (zur Hausen et al (1979) Proc. Natl. Acad. Sci. USA 76, 782-785); RTX did not induce typical phorbol ester responses in cultured cell systems (zur Hausen et al (1979) Proc. Natl. Acad. Sci. USA 76, 782-785 and Driedger et al (1980) Cancer Res. 40, 1400-1404); and RTX did not efficiently compete for phorbol ester binding to protein kinase C (Driedger et al (1980) Proc. Natl. Acad. sci. USA 77, 567-571).
A free 20-hydroxyl group is critical for phorbol ester activity (Hecker, E. (1978) in Carcinogenesis, Mechanism of Tumor Promotion and Cocarcinogenesis, eds. Slaga, T.J., Sivak, A. and Boutwell, C.K. (Raven Press, New York), Vol. 2, pp. 11- 48). RTX, in contrast, is esterified at this position with 4-hydroxy-3-methoxyphenylacetate, and this sub- stituent has been shown to be essential for its unusual irritant activity (Adolph et al (1982) J. Nat. Prod. 45, 347-354 and Schmidt et al (1979) Inflammation 3, 273- 280). Strikingly, a 4-hydroxyl-3-methoxy-phenyl sub- stituent is also a critical feature of capsaicin, the major pungent constituent of red pepper and other plants of the genus Capsicum (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55 and Szolcsanyi et al (1975) Arzneim-Forsch. (Drug Res.) 25, 1877-1881) (See Figure 1). Structure-activity analysis of capsaicin congeners, moreover, indicates that an ester linkage such as is found in RTX is adequately tolerated in place of the amide linkage present in the opposite orientation in capsaicin. Capsaicin causes diverse physiological effects, of which pain, neurogenic edema, and hypothermia are prominent examples (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55, Szolcsanyi et al (1975) Arzneim-Forsch. (Drug Res.) 25, 1877-1881 and Buck et al (1986) Pharmacol. Rev. 38, 179- 226). Acute response is followed by long-lasting desensitization. The postulated cellular mechanism is by transient activation followed by desensitization and, under some conditions, degeneration of C-fiber sensory afferent neurons (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55, Buck et al (1986) Pharmacol. Rev. 38, 179-226 and Scadding, J.W. (1980) J. Anat. 131, 473-484). These neurons contain substance P and associated neuropeptides. The bio- chemical mechanism for this effect of capsaicin on C- fibers is not known.
The inventors have confirmed the possible homology of RTX and capsaicin (i.e. both compounds pro¬ duced a dramatic fall in body temperature in mice followed by cross-tolerance (deVries et al (1988) sub¬ mitted, Life Sciences) and have now compared the potencies and xn_ vivo activities of RTX and capsaicin in detail, as discussed hereinbelow.
Accordingly, the inventors have characterized a commercially available but largely unstudied natural product, resiniferatoxin. RTX qualitatively resembles capsaicin in its activity, but differs quantitatively in potency (i.e. 10'*' - 104 fold more potent) and in relative spectrum of actions. Resiniferatoxin thus causes desensitization to neurogenic inflammation, to chemically and thermally induced pain, and to responses involving sensory afferent pathways including C-fibers and the hypothalamic temperature control region. The induced desensitization may have application in arthritis, asthma, allergic responses, fever, pain associated with cancer or Herpes virus infection, and in biological pro- cesses mediated by substance P or other neuropeptides depleted by capsaicin treatment.
As indicated above, resiniferatoxin has similar effects to capsaicin, but differs in its much greater potency - up to 10 , which should remarkably reduce side effects and permit easier application (i.e. smaller volume or absorption through inefficient routes) . RTX also shows a somewhat different spectrum of action, enabling greater desensitization at a given level of systemic toxicity and greater desensitization relative to acute induction of pain.
Moreover, desensitization by resiniferatoxin can be activated by topical, intravenous, intra- peritoneal, and subcutaneous administration. RTX may be administered to an animal such as a mammal (e.g. mouse, r t or human) .
Furthermore, it should be noted that capsaicin exerts its actions on all mammals examined, but not on birds and lower vertebrates (Monsereenusorn et al (1982) CRC Crit. Rev. Toxicol. 10, 321-339). Based on the resemblances in the activities of capsaicin and resini¬ feratoxin documented in this application, we extrapolate that the effects of resiniferatoxin are not limited to rats and mice but extend to man as well.
Resiniferatoxin, an extremely irritant diterpene present in several members of the genus Euphorbia, produced an 8°C decrease in the rectal temper- ature of mice with an effective dose in the range of 2-20 μg/kg. The structurally related natural product capsaicin produced a similar magnitude of fall in body temperature albeit with 1000-fold lower potency. Tolerance to the hypothermic effects of both drugs developed readily and cross-tolerance between drugs was observed. The extreme potency of resiniferatoxin should facilitate biochemical analysis of the mechanism of action of this class of compounds.
RTX was remarkable for its potency in the mouse ear reddening assay. Its 50% effective dose, 1.6 x 10" moles/ear, indicated a 1000-fold greater potency than that of the most active of the typical phorbol esters, phorbol 12-myristate 13-acetate. (Adolf, W. , Sorg., B., Hergenhahn, M. and Hecker, E. (1982) J_. Nat. Prod. , Vol. 45, pp. 347-354).
Although the mechanism of action of RTX has not been extensively studied, its mechanism is clearly distinct from that of the phorbol esters for the follow¬ ing reasons: (1) Whereas phorbol esters cause comparable ear reddening at 3 and at 24 hours after application, the irritant activity of RTX is only found at the earlier time point (Adolf, W. et al (1982) J_. Nat. Prod. , Vol. 45, pp. 347-354; Schmidt, R.J. et al
(1979). Inflammation, Vol. 3, pp. 273-
280; Hergenhahn, M. , et al (1982) J Cancer
Res. Cli . Oncol. , Vol. 104, pp. 31-39.
(2) RTX is not tumor promoting and is much less potent than typical phorbol esters at eliciting responses in a range of cultured cells. (zur Hausen, H. , Bornkamm, G.W., Schmidt, R. and Hecker, E. (1979) Proc. Natl. Acad. Sci. U.S.A., Vol. 76, pp. 782- 785; Driedger, P.E. and Blumberg, P.M. (1980) Cancer Res. , Vol. 40, pp. 1400- 1404).
(3) RTX does not compete for phorbol ester binding sites on protein kinase C.
(Driedger, P.E. and Blumberg, P.M. (1980)
Proc. Natl. Acad. Sci. U.S.A., Vol. 77, pp. 567-571).
RTX, the active ingredient of the present invention, can be made into pharmaceutical compositions by combination with appropriate medical carriers or diluents. For example, RTX can be dissolved in oils, propyleneglycol or other solvents commonly used to pre¬ pare injectable solutions. Suitable carriers include physiological saline, polyethylene glycol, ethanol, sesame oil, cremophor and isopropyl myristate. For topical application, RTX can be formulated as an ointment or cream.
The following methods and excipients are merely exemplary and in no way limit the invention.
The compounds of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds. The compounds of the present invention may be formulated into preparations for injections by dis- solving, suspending or emulsifying them in aqueous solvents such as normal saline. Dextrose 5%, or non- aqueous solvent, such as vegetable oil, synthetic ali¬ phatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspend¬ ing agents, emulsifying agents, stabilizers and preserva¬ tives. The compounds of the invention may be combined with other compounds having the desired effect.
The desirable dose of the compounds of the present invention, varies with the subject, drug form, method and period of administration. However, in order to obtain desirable effects, generally it is recommended to administer 0.1 x 10~3 to 5 x 10"2 mg/kg, preferably 0.1 x 10~3 to 5 x 10~3 mg/kg, body weight of the com¬ pounds of the present invention for single application, or less upon multiple application. In terms of composi¬ tion, compounds should be present between .0001 to 10% by weight, preferably .0001 to 1% by weight.
Accordingly, the following experiments demon¬ strate that resiniferatoxin is an extremely irritant diterpene present in the latex of several members of the genus Euphorbia. Its mechanism of action is clearly distinct from that of structurally related phorbol esters. Since RTX possesses a 4-hydroxy-3-methoxyphenyl substituent, a key feature of capsaicin, the major pungent ingredient of plants of the genus Capsicum, the ability of RTX to induce typical capsaicin responses is examined. The treatment of rats with RTX (Example 1), like treatment with capsaicin, causes hypothermia, neuro¬ genic inflammation and pain. These responses are followed by loss of thermoregulation, by desensitization to neurogenic inflammation, and by chemical and thermal analgesia, with cross-tolerance between RTX and capsaicin. RTX is 3-4 orders of magnitude more potent than capsaicin for the effects on thermoregulation and neurogenic inflammation. RTX is only comparable in potency to capsaicin, however, the assays for induction of acute pain, and the desensitization to acute pain appears to require less RTX than did desensitization for the other responses. Thus, RTX acts as an ultrapotent capsaicin analog and may distinguish between subclasses of capsaicin response.
The following Examples are intended to illu- strate the claimed invention and will enable others skilled in the art to understand the invention more com¬ pletely. However, the invention should not be interpreted as being limited to only these representative examples.
EXAMPLE 1 Methods
Sprague-Dawley rats (females, 250-300 g) are purchased from the Zivic-Miller Laboratories, (Zelienople, PA). Animals are allowed access to food and water ad libitum through the course of the experiments. The numbers of animals used in different experimental groups are indicated in the legends to 1-3 tables and Figures 1-10. RTX (MW 628) is obtained from Chemicals for Cancer Research, Inc. (Chanhassen, MN), and Capsaicin (MW 305) from Polysciences (Warrington, PA). The com¬ pounds are administered in 10% ethanol/ 10% Tween-80/ 80% physiological saline solution unless otherwise indicated. Pain-Inducing Potency Acute pain-inducing potency of the compounds is assessed as described by Jancso et al (Jancso et al (1961) Acta Physiol. Acad. Sci. Hung. 19, 113-131), which is herein incorporated by reference. Briefly, solutions at ten-fold increasing concentrations of compound in physiological saline are dropped into the eyes of rats and the number of protective movements (eye-wipings with the foreleg) is determined. To minimize the irritant being rinsed out by lacrimation, the instillation is repeated once. The solution by itself induced no wipings. The concentrations inducing an equal reaction of 10 wipings (moderate pain-producing potency) is calcu¬ lated from the dose-response curves (Szolcsanyi et al (1975) Arzneim-Forsch. (Drug Res.) 25, 1877-1881). Except for these experiments, both RTX and capsaicin are applied under light ether anesthesia to avoid unnecessary pain. Analysis of Vascular Permeability Changes in vascular permeability to serum albumin are analyzed using the Evan's blue technique (Saria et al (1983) J. Neurosci. Meth. 8, 41-49). From 8-12 rats at each time point and dose are anesthetized with pentobarbitone (40 mg/kg), the right jugular vein is exposed, and 20 mg/kg of Evan's blue (1% Evan's blue solution in physiological saline containing 100 IU/ml heparin) is injected (Saria et al (1983) J. Neurosci. Meth. 8, 41-49). At the indicated times (e.g. typically 30 minutes unless otherwise indicated) after injection, the animals are killed and the tissues (e.g. skin, lung, ovary, stomach, intestine) excised. The excised tissues are blotted with filter paper to remove excess fluid, immediately weighed, and then placed in 4.0 ml formamide for 24 hours at 50°C to extract the Evan's blue. Evan's blue is quantitated by determining absorption at 620 nm in a Shimadzu spectrophotometer. Extent of Edema
The extent of edema is measured by treating the hind paw with the irritant or solvent. At the indicated time (e.g. 30 minutes) the animal is killed, 1 cm diameter skin punches are removed and quickly weighed, and after drying for 24 hours at 50°C the skin punches are reweighed. The difference in the water content between irritant-and solvent-treated animals represents the extent of edema (Fischer et al (1988) Cancer Res. 48, 659-664).
To obtain direct evidence for the neurogenic origin of the observed inflammation, from 10-14 denervated rats are purchased from Zivic-Miller Laboratories. Determination of edema in response to RTX and is carried out 3 days after the left saphenous nerve had been cut in the upper thigh (Jancso et al (1967) Br. J. Pharmacol. Chemother. 31, 138-151). Irritants are applied on both hind paws; the right intact paw serves as a positive control. Body Temperature The body temperature of the rats are determined as described by Szikszay et al (1982) Naunyn- Schmiedeberg's Arch. Pharmacol. 320, 97-100. Rats are habituated prior to treatment to the room temperature (20°C) and to the small-animal temperature probe (Cole- Par er, Chicago, IL) which is introduced rectally to a depth of 5 cm.
Desensitization against acute chemical pain is examined using the eye-wiping test. RTX is injected subcutaneously and 4 hours later capsaicin is instilled into the eye. Antinociceptive effect against chronic pain is tested by the method of Dubuisson et al (1977) Pain 4, 161-174. 5% formalin solution is injected under the plantar surface of the right forepaw 4 hours after topical RTX or capsaicin administration. Behavior of animals is scored as described in Dubuisson et al (1977) Pain 4, 161-174 during an observation period of 60 minutes. Heat nociception is examined in the tail- immersion test at 50°C (D'Amour et al (1941) J. Pharmacol. Exp. Ther. 72, 74-79 and Gamse, R. (1982) Naunyn-Schmiedeberg's Arch. Pharmacol. 320, 205-216). Desensitization against the inflammatory response is determined by measuring extravasated Evan's blue after a high paw has been painted with xylene, an effective inducer of neurogenic inflammation (Jancso et al (1967) Br. J. Pharmacol. Chemother. 31, 138-151). Desensitiza¬ tion is also determined by measuring extravasated Evan's blue after dextran is injected under the hind paw skin (25 ug in a volume of 50 ul); dextran releases vasoactive substances without causing neurogenic inflammation (Jancso et al (1967) Br. J. Pharmacol. Chemother. 31, 138-151) . Results
Capsaicin has profound effects on thermoregula- tion in mammals (Jancso-Gabor et al (1970) J. Physiol. (Lond.) 206, 495-507, Virus et al (1979) Life Sci. 25, 1273-1284, Monsereenusorn et al (1982) CRC Crit. Rev. Toxicol. 10, 321-339 and Yaksh et al (1979) Science (Wash. D.C.) 206, 481-483). RTX, like capsaicin, causes a 2-3°C drop in rectal temperature 1 hour after treatment of rats maintained at 20°C (See Figure 2). The ED50 for RTX is 3 x 10 g/kg, compared to an ED^Q for capsaicin of 2 x 10~3 g/kg.
Repeated treatment with capsaicin causes com¬ plete desensitization to its hypothermic effects (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55 and Yaksh et al (1979) Science (Wash. D.C.) 206, 481-483). Similarly, treatment with RTX at a dose of 1 x 10 g/kg causes an abrupt decrease in body temperature which largely returns to control levels after 3 hours (See Figure 3A) . A second treatment with RTX causes only a limited response and further treatments have no effect. The desensitized animals show cross-desensitization to capsaicin (10 g/kg), whereas control animals show marked hypothermia to capsaicin.
Capsaicin desensitized rats display an inability to adapt to heat stress (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55 and Virus et al (1979) Life Sci. 25, 1273- 1284). If subjected to elevated ambient temperature (38°C), RTX-desensitized rats show a steady rise in body temperature, ultimately leading to collapse, in contrast to control animals (See Figure 3B) .
Desensitization with capsaicin can be achieved either by means of a single large dose or of repeated incremental doses (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55 and Buck et al (1986) Pharmacol. Rev. 38, 179-226). The former procedure is more convenient for quantitation and com¬ parison. Therefore, the dose dependency was determined for desensitization to RTX-induced hypothermia following pretreatment with a single, subcutaneous injection of RTX (See Figure 4) . The dose response curve was extremely steep and yielded an ED5Q of 5 X 10~" g/kg. This value is approximately an order of magnitude greater than the EDcjQ for the direct hypothermic effect, but similar to that which gives a maximal response.
Induction of neurogenic inflammation is a second prominent feature of the capsaicin response (Jancso et al (1967) Br. J. Pharmacol. Chemother. 31, 138-151, Virus et al (1979) Life Sci. 25, 1273-1284 and Monsereenusorn et al (1982) CRC Crit. Rev. Toxicol. 10, 321-339). Inflammation was quantified by measuring extravasation of Evan's blue dye. Like capsaicin, RTX applied topically to the hind paw of rats causes dramatic extravasation. The ED^Q for topical administration of RTX is 3 x 10 g/paw, compared to an ED^Q for capsaicin of 3 x 10~2 g/paw (See Figure 5). The kinetics of edemas formation are determined from the water content of the hind paw skin as a function of time. No edema formation is observed up to 30 minutes; the water content reaches its peak at 90 minutes; and the edema disappears by 4 hours (See Figure 7). The solvent acetone by itself did not have any effect.
Since the inflammation caused by capsaicin is neurogenic, the inflammatory response thereof is compared to RTX in intact paws and in paws which have been dener- vated by transection of the saphenous nerve in the thigh of the rat. Denervation totally blocks the inflammatory response to RTX, measured either by Evan's blue extra¬ vasation or by increase in water content as shown in Table 1 below. TABLE 1
Effect of Denervation on RTX-induced Edema
Treatment Extravasated Evan's Blue ng/ g tissue solvent only 11.31 +_ 2.49
80 ug RTX on denervated paw 8.86 ± 1.36
80 ug RTX on intact paw 84.22 +.11.35 Water content of skin. % solvent only 65.1 50 ug RTX on denervated paw 64.9 50 ug RTX on intact paw 71.6
The left saphenous nerve is cut 3 days before the experiment. Irritant is applied topically in 50 ul acetone on both hind paws; the intact paw serves as a positive control. Values are the mean +_ SEM standard error of the mean for 10 - 14 animals in 2 experiments.
Although Evan's blue extravasation is quanti¬ fied only following topical treatment of the paw with RTX, visual examination of systematic extravasation after intravenous injection of RTX was performed (0.1 ug/kg) . RTX induces a similar pattern of extravasation to that reported for capsaicin (Saria et al (1983) Naunyn- Schmiedeberg's Arch. Pharmacol. 324, 212-218): extrava¬ sation in skin, lung, ovary, and most other tissues, but characteristically not in stomach and intestine.
Capsaicin treatment is followed by desensitiza¬ tion to neurogenic inflammation (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55, Buck et al (1986) Pha acol. Rev. 38, 179-226, Virus et al (1979) Life Sci. 25, 1273-1284 and Monsereenusorn et al (1982) CRC Crit. Rev. Toxicol. 10, 321-339). Injection of RTX subcutaneously likewise pre¬ vents Evan's blue extravasation upon challenge 4 hours later with either RTX or capsaicin as shown in Table 2 below. RTX pretreatment similarly blocks response to xylene, another potent neurogenic irritant (Jancso et al (1967) Br. J. Pharmacol. Chemother. 31, 138-151), but has - 16 -
little effect on the response to dextran, a potent irritant with a non-neurogenic mechanism.
TABLE 2 Specificity of RTX-Desensitization Treatment Evan's blue extravasation*
% of control xylene (50 ul/paw) 14.4 capsaicin (20 mg/paw) 12.6
RTX (50 ug/paw) 3.5 dextran (25 ug in 50 ul saline) 118
RTX (300 ug/kg) is injected under the back skin. Controls are injected with vehicle alone. 4 hours later xylene, capsaicin, or RTX is painted on the skin of the hind paw or dextran is injected under the skin. Evan's blue extravasation is determined 10 minutes after xylene or dextran treatment and 30 minutes after capsaicin or RTX treatment. Values are the mean for 8-10 animals in 2 experiments.
The desensitization induced by subcutaneously injection of RTX is rapidly expressed and of long dura¬ tion. Inhibition of neurogenic inflammation is greater than 70% by 1 hour and achieves a level plateau by 4 hours which is maintained over the next 4 days. Responsiveness only partially returns by 7 days after treatment.
The Dgø for inhibition of xylene-induced
Evan's blue extravasation by subcutaneous injection of
RTX is 5 x 10"6 g/kg (See Figure 4). Similarly, ED50 for inhibition of xylene-induced Evan's blue extravasation by subcutaneous injection for capsaicin is 10 g/kg. In the case of capsaicin, the maximum tolerated subcutaneous dose affords only partial desensitization upon a single administration, whereas complete desensitization is attainable with RTX. Capsaicin potently stimulates chemogenic pain receptors (Jancso, N. (1968) in Pharmacology of pain
(Pergamon Press, Oxford), Vol. 9, pp. 33-55 and Monsereenusorn et al (1982) CRC Crit. Rev. Toxicol. 10, 321-339), and the irritancy to the eye has been utilized most extensively to quantitate capsaicin structure- activity relations (Szolcsanyi et al (1975) Arzneim- Forsch. (Drug Res.) 25, 1877-1881 and Jancso et al (1961) Acta Physiol. Acad. Sci. Hung. 19, 113-131). As in the other assays (e.g. described above), RTX proves to be more potent than capsaicin (See Figure 6A) . However, the difference in potency is much less than the 10 -10 -fold difference observed for the hypothermic and inflammatory effects. In addition, a latency period of 5-10 seconds is observed for RTX treatment compared to an immediate response upon capsaicin instillation, and the duration of the response is longer. Extension of the dose response curves for the eye wiping response to higher levels is not carried out so as to avoid undue pain.
Injection of RTX subcutaneously causes desensi¬ tization of the eye wiping response to capsaicin. The ED5Q for RTX is 1 x I0~7 g/kg, a dose significantly less than that for desensitization to the hypothermic and inflammatory effects. This difference is confirmed in animals treated with RTX at 1 x 10 g/kg and assessed for both the eye wiping response and Evan's blue extrava¬ sation. RTX desensitization to chemical and thermal nociception is also examined in two other standard assays such as (i) response to formalin injection into the fore¬ paw (Dubuisson et al (1977) Pain 4, 161-174 and Hayes et al (1981) Neuropharmacol 20, 505-511) and (ii) tail immersion into 50°C water (D'Amour et al (1941) J. Pharmacol. Exp. Ther. 72, 74-79 and Gamse, R. (1982) Naunyn-Schmiedeberg's Arch. Pharmacol. 320, 205-216). RTX blocks nociception in both cases and does so with greater potency than does capsaicin as shown in Table 3 below. TABLE 3 Effect of RTX Pretreatment on Sensory Functions Pretreatmenta Pain-inde Latency timec
(sec) Solvent only 3.0 6.8 +_ 1.3
RTX, 1 ug/paw 3.0 7.2 + 1.3
RTX, 10 ug/paw 1.5 6.0 + 1.0
RTX, 100 ug/paw 0.2 42.0 +_ 9.3 capsaicin, 3 mg/paw 0.2 19.4 +_ 8.1 aCapsaicin and RTX at the indicated doses are injected under the plantar surface of the forepaw in a volume of 50 ul.
4 hours after pretreatment, 50 ul of 5% formalin solu¬ tion is injected into the treated paw. The behavior of the animals is observed for 1 hour after the injection and the pain response is quantitated as described (Dubuisson et al (1977) Pain 4, 161-174). cIn the same animals 8 hours after pretreatment, the tail withdrawal latency time is determined (D'Amour et al (1941) J. Pharmacol. Exp. Ther. 72, 74-79 and Gamse, R. (1982) Naunyn-Schmiedeberg's Arch. Pharmacol. 320, 205- 216). Values are the mean +_ SEM for 6-10 animals in two (2) experiments. Discussion The data strongly suggests that RTX functions as a capsaicin analog. RTX induces each of the three characteristic acute physiological responses to capsaicin which are examined - hypothermia, neurogenic inflamma¬ tion, and pain. The acute response to RTX is followed by desensitization, a typical feature of capsaicin but not of unrelated irritants. The RTX-desensitized animals, moreover, displays cross-tolerance to capsaicin.
Although RTX mimicks capsaicin in its quali¬ tative action, quantitatively it differs drammatically in potency. RTX is much more potent than capsaicin for induction of hypothermia (7 x 10 -fold, administered subcutaneously) , for induction of neurogenic inflammation (1 x 103-fold, applied topically), and for desensitiza¬ tion of neurogenic inflammation (2 x 10 -fold, admini¬ stered subcutaneously) . In studies in the mouse, (Example 2 below)^ RTX is also found to be 2 x 10 -fold more potent for induction of hypothermia.
In addition to being more potent than capsaicin as demonstrated by the above assays, RTX also displays a different spectrum of action. The potency of RTX in the eye wiping assay, a measure of acute pain, is within a factor of 2 of that of capsaicin, in contrast to the 10 - 105-fold difference described above. For desensitization of neurogenic inflammation, a single dose of RTX affords complete desensitization, whereas the maximum tolerated dose of capsaicin causes only partial desensitization. This qualitative difference may reflect different rela¬ tive toxicities upon subcutaneous administration. The maximum tolerated dose of RTX is approximately 100-fold its EDt-jQ for desensitization of neurogenic inflammation, whereas the ED5Q for capsaicin is the maximum tolerated dose. Although differences in pharmacokinetics may explain some of the disparities in relative potencies, it seems unlikely to account for the differences of 10 -fold which are observed.
Comparison of the potencies of RTX for desensi- tization in the eye wiping and Evans blue extravasation responses also imply heterogeneity of action. Desensiti¬ zation in the eye-wiping assay is achieved with a 100- fold lower dose of RTX than in the latter assay, although desensitization with RTX is carried out in the same fashion in both cases and indeed both responses could be assessed in the same animals.
A previous investigation of capsaicin and related analogs likewise suggests different patterns of responses for different congeners. Whereas capsaicin causes both acute irritation and long lasting desensiti¬ zation, zingerone, the pungent ingredient in ginger, lacks desensitizing activity (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55). It has been suggested that the acylamide linkage, which is present in capsaicin but missing in zingerone, might be essential for desensitization (Jancso, N. (1968) in Pharmacology of pain (Pergamon Press, Oxford), Vol. 9, pp. 33-55). The high desensi¬ tizing potency of RTX argues against this suggestion.
RTX represents a powerful new tool for probing mechanisms of pain, neurogenic inflammation, and thermo- regulation. Its high potency should facilitate receptor analysis; its structural relationship to the phorbol- related diterpenes affords a new family of derivatives to define the capsaicin pharmacophor . Given the potential therapeutic implications of C-fiber desensitization, the unique spectrum of action of RTX is of particular interest.
The figures of Example 1 are discussed in greater detail hereinbelow.
Figure 1 shows a comparison of the structures of capsaicin and resiniferatoxin.
Figure 2 shows the induction of hypothermia in rats by RTX or capsaicin. The fall in rectal temperature is measured 1 hour after the subcutaneous injection of RTX ( • ) or capsaicin (o) at the indicated doses. Points represent the mean for 10 animals in 2 experi¬ ments.
Figure 3 shows the body temperature of the rats as a function of time after administration of RTX.
A) Animals are injected with 100 ug/kg of RTX at the times indicated by the solid arrows ( • ) . Cross- tolerance is examined by injection of 10 mg/kg capsaicin (open arrows). Vehicle controls are injected with the same dose of capsaicin (o). Values are the mean for 6-8 animals in 2 experiments. B) Vehicle controls ( A ) or animals desensi¬ tized by subcutaneous injections with a cumulative dose of 400 ug/kg RTX ( B ) are exposed to high ambient temperature (38°C). Hypothermia results in collapse of the rats. Values are the mean for 8 animals in two experiments.
Figure 4 shows the dose dependence of desensi- tization to hypothermic action and Evans blue extravasa¬ tion. Extravasation is induced by xylene (50 ul/paw) 4 hours after RTX ( A ) or capsaicin ( Δ ) is in ected sub- cutaneously at the indicated doses. Values are the mean +_ SEM for 8-12 animals in 3 experiments. Q represents xylene-induced Evans blue extravasation in vehicle con¬ trols. Hypothermia is induced by injection of 100 g/kg RTX, a dose providing a maximal response, 12 hours after RTX pretreatment ( • ) at the indicated doses. The time interval is chosen to avoid any interference between hypothermia produced by the pretreatment and the test dosage. Values are the mean for 8-10 animals in 2 experiments.
Figure 5 shows the dose dependence of Evans blue extravasation induced by topical RTX or capsaicin. RTX ( • ) or capsaicin ( o ) at the indicated doses is painted on the skin of the hind paw in 50 ul acetone. Extravasation is measured 30 minutes after application. Points are the mean +_ SEM for 10 animals in 2 experi¬ ments. Figure 6 shows the dose dependence of eye wiping in response to instillation of RTX or capsaicin.
A) RTX ( • ) or capsaicin ( o ) solutions at the indicated concentrations is instilled into the eyes of rats. Each value is the mean +_ SEM for 12 animals in 3 experiments.
B) Animals are treated by subcutaneous injec¬ tion of RTX ( L ) at the indicated doses and the eye- wiping response to 10~3 g/ml capsaicin is determined 6 hours later. Values are the mean +_ SEM for 8-10 animals in 2 experiments.
Figure 7 shows the water content of the hind paw skin of rats after RTX treatment. Resiniferatoxin, 50 ug, was applied to the hind paw skin of rats and the water content of the skin was measured at the illustrated times, ranging between 10 minutes and 4 hours. Points represent the average values from 5 animals at each time of application. The experiment was repeated once and gave the same results.
EXAMPLE 2 Materials and Methods
Body temperature of the mice is determined essentially as described by Obal and coworkers. (Szikszay, M. , Obal, F. Jr. and Obal, F. (1982) Naunyn- Schmiedeberq's Arch. Pharmacol., Vol. 320, pp. 97-100).
From 10-36 female CD-I mice, 25-30 g, are habituated prior to treatment to both the experimental room (22-23°C) and to the small-animal temperature probe (Cole-Parmer, Chicago, IL) which is introduced rectally to a depth of 2.5 cm. Drugs are prepared in 10% ethanol/10% Tween-80/80% phosphate buffered saline and administered in volumes of less than 0.1 ml at the indi- cated doses of 0.2-40 ug/kg of resiniferatoxin or 2-15 mg/kg of capsaicin. Animals are allowed free access to food and water through the course of the experiments.
Dose response curves are analyzed by the curve- fitting program KA (McPherson, G.A., Molenaar, P., Raper, C. and Malta, E. (1983) J. Pharmacol. Methods, Vol. 10, pp. 231-241).
Resiniferatoxin (M.W. 628) was obtained from Chemicals for Cancer Research (Chanhassen, MN) and capsaicin (M.W. 305) from Polysciences (Warrington, PA). Results
Capsaicin (15 mg/kg) produces a profound drop in the body (rectal) temperature of mice upon subcu¬ taneous injection as shown in Figure 8. The effect is maximal at 1 hour and returns to baseline by 3 hours. RTX (20 g/kg) causes a comparable drop in body temper¬ ature. However, the duration of action of RTX is several-fold longer. Relative potencies of capsaicin and RTX are determined measuring the drop in body temperature 1 hour after treatment. RTX has a 50% effective dose of 3 g/kg while capsaicin displays a 50% effective dose of 7 mg/kg as shown in Figure 9. The drop in body temperature induced by both agents at maximally tolerated doses is approximately 8°C. When given intraperitoneally, capsaicin produces only transient effects and then only at doses higher than those required upon subcutaneous administration. Results obtained with RTX appear inde¬ pendent of administration route (see Figures 8 and 10).
Marked tolerance to the hypothermic effects of capsaicin develops by the second day of treatment as shown in Figure 10. Tolerance also develops to RTX although over a longer period of time. Exposure to either drug appears to produce a resting state of hyper- thermia of approximately 1.5°C. Following 4 days of treatment with either capsaicin or RTX, the hypothermic response of the animals to the other compound is examined (Figure 10). The capsaicin pre-treated animals are com¬ parably tolerant to RTX; the RTX pre-treated animals are partially tolerant to capsaicin. Discussion
RTX and capsaicin share a capacity to dramati- cally depress the rectal temperature of mice. This effect may in part be due to the irritant/vasodilatory action of both compounds, contributing to enhanced heat loss. In addition, the application of capsaicin to dis¬ creet areas of the brain has strongly argued for a central site of action of this compound on thermoregula¬ tion (Monsereenusorn, Y., Kongsamut, S. and Pezalla, P.D. (1982) CRC Crit. Rev. Toxicol., Vol. 10, pp. 321-339). The rapidity and degree of hypothermia induced by RTX may also argue for a central site of action. Capsaicin has been reported to potently inter¬ act with the hepatic microsomal drug-metabolizing system and to irreversibly bind to microsomal proteins (Miller, M.S., Brendel, K., Burks, T.F. and Sipes, I.G. (1983) Biochem. Pharmacol. , Vol. 32, pp. 547-551). Suscepti¬ bility to biotransformation may explain the relatively short duration of action of capsaicin and its lack of potency when administered intraperitoneally.
The mechanism by which tolerance develops to the effects of these hypothermic agents probably involves some component of enhanced metabolic breakdown, particularly considering the interaction of capsaicin with drug-metabolizing systems described above. The observed elevation in resting temperature following initial exposure, noted here and described previously for capsaicin in the rat (Jancso-Gabor, A., Szolcsanyi, J. and Jancso, N. (1970) J. Phvsiol., Vol. 208, pp. 449-459; Szikszay, M. et al, (1982) Naunvn-Schmiedeberq's Arch. Pharmacol, Vol. 320, pp. 97-100) is indicative of some form of central response to the hypothermic stress and may contribute to the tolerance and cross-tolerance phenomena observed. The remarkable potency of RTX as both an irritant and hypothermic agent indicates its potential as a pharmacological tool. Elucidation of the mechanism of action of capsaicin has been hampered by the relatively modest potency of this drug. Comparisons between the actions of RTX and capsaicin in various other paradigms may prove fruitful in delineating the mechanisms of these interesting natural products.
The figures of Example 2 are described in greater detail hereinbelow. Figure 8 shows the body temperature in mice as a function of time after administration at time "0" of vehicle ( £ ), 20 /jg/kg RTX (•) or 15 mg/kg capsaicin ( ) subcutaneously. Each data point is the mean value from 4 animals +_ s.e.m.. Figure 9 shows the dose response curves for change in body temperatures 1 hour after treatment with RTX (•) or capsaicin ( - ) . RTX was administered i.p. (intraperitoneally); capsaicin was administered s.c. Each point represents the difference between mean values pre-and post-treatment for 2-4 animals in five individual experiments. Figure 10 shows the effect of repeated treat¬ ments with RTX or capsaicin on body temperature. Values represent the mean and s.e.m. of values obtained from 4 animals injected s.c. Body temperatures are measured before ( o / O , ) and one hour after ( V , • / ♦ ) treatment. Vehicle control ( D )• Treatment with
RTX (0, o) at a rate of 20 /jg/kg on days 1 and 2 and 40 g/kg on days 3 and 4. On day 5 cross-tolerance is examined by injection of 15 mg/kg capsaicin. Treatment with capsaicin ( , A ) at a dose of 15 mg/kg on days 1 and 2 and 30 mg/kg on days 3 and 4. On day 5 cross- tolerance is examined by injection of 20 g/kg RTX.
The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.

Claims

WHAT IS CLAIMED IS:
1. A method for desensitizing a subject animal, which comprises administering to said subject animal a desensitizing effective amount of resinifera- toxin for desensitizing the subject to neurogenic inflammation, to chemically and thermally induced pain, to responses involving sensory afferent pathways sensi¬ tive to capsaicin and to responses involving the hypo¬ thalamic temperature control region, and a pharm- aceutically acceptable carrier therefor.
2. The method of claim 1, wherein the resini¬ feratoxin is administered topically, subcutaneously or intraperitoneally.
3. The method of claim 1, wherein resinifera- toxin is administered in the range of 1 x 10~5 mg/kg to 5 x 10 mg/kg to the subject.
4. The method of claim 1, wherein the subject is a mammal.
5. The method of claim 4, wherein the subject mammal is a mouse, rat, domestic animal, or human.
6. The method of claim 5, wherein the domestic animal is a dog, cat, horse, cow, pig, goat or sheep.
7. The method of claim 1, wherein the resinferatoxin is administered by single or multiple application.
PCT/US1989/004769 1988-10-24 1989-10-24 Use of resiniferatoxin and analogues thereof to cause sensory afferent c-fiber and thermoregulatory desensitization WO1990004389A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE89912770T DE68910834T2 (en) 1988-10-24 1989-10-24 Use of resiniferatoxin and its analogs to make the inflammation-sensitive C-fiber insensitive by temperature control.
AT89912770T ATE97320T1 (en) 1988-10-24 1989-10-24 USE OF RESINIFERATOXIN AND ITS ANALOGUES TO INDENSIFY THE INFLAMMATION SENSITIVE C-FIBER THROUGH TEMPERATURE CONTROL.
JP2500630A JPH0729919B2 (en) 1988-10-24 1989-10-24 Use of resiniferatoxin and its homologues to cause afferent sensory C-fibers and thermoregulatory desensitization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US261,627 1988-10-24
US07/261,627 US4939149A (en) 1988-10-24 1988-10-24 Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization

Publications (1)

Publication Number Publication Date
WO1990004389A1 true WO1990004389A1 (en) 1990-05-03

Family

ID=22994143

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/004769 WO1990004389A1 (en) 1988-10-24 1989-10-24 Use of resiniferatoxin and analogues thereof to cause sensory afferent c-fiber and thermoregulatory desensitization

Country Status (8)

Country Link
US (2) US4939149A (en)
EP (1) EP0439549B1 (en)
JP (1) JPH0729919B2 (en)
AU (1) AU619930B2 (en)
CA (1) CA2001194C (en)
DE (1) DE68910834T2 (en)
IL (1) IL92082A0 (en)
WO (1) WO1990004389A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020867A1 (en) * 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5744490A (en) * 1989-05-15 1990-12-18 Afferon Corporation Composition and method for neural desensitization
US5021450A (en) * 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) * 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
JP2594485B2 (en) * 1990-08-29 1997-03-26 アメリカ合衆国 Bird food containing capsaicin or a derivative or analog thereof
US5629045A (en) * 1992-09-17 1997-05-13 Richard L. Veech Biodegradable nosiogenic agents for control of non-vertebrate pests
US6063381A (en) * 1993-05-19 2000-05-16 Staggs; Jeff J. Therapeutic uses of pungent botanicals and their related compounds
US6635659B1 (en) * 1995-03-20 2003-10-21 Arrie Kegler Topical formulation for arthritic symptoms treatment
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
US5869533A (en) * 1996-04-23 1999-02-09 Holt; Stephen D. Non-irritating capsaicin formulations and applicators therefor
US5856361A (en) * 1996-04-23 1999-01-05 Medical Merchandising, Inc. Pain reliever and method of use
CN100413961C (en) * 1996-09-05 2008-08-27 研究发展基金会 Inhibition of nuclear transcription factor NF- kappa B by caffeic acid phenethyl ester (CAPE), derivatives of CAPE, capsaicin (8-methyl-n-vanillyl-6-nonenamide) and resiniferatoxin
EP1201241B8 (en) † 1997-03-13 2010-10-27 James N. Campbell Compositions containing capsaicin or capsaicin analogues and an anesthetic
WO1999009970A1 (en) * 1997-08-28 1999-03-04 Afferon Corporation Urinary incontinence therapy
US6790207B2 (en) * 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6802841B2 (en) 1998-06-04 2004-10-12 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction
US20110071468A1 (en) * 1998-06-04 2011-03-24 Mederi Therapeutics, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction
US6653352B2 (en) 1999-09-29 2003-11-25 Medical Merchandising, Inc. Pain reliever and method of use
US6348501B1 (en) 1999-09-29 2002-02-19 Medical Merchandising, Inc. Lotion compositions utilizing capsaicin
US6197823B1 (en) 1999-09-29 2001-03-06 Medical Merchandising, Inc. Pain reliever and method of use
CN1443170A (en) * 2000-07-20 2003-09-17 神经原公司 Capsaicin receptor ligands
US20040146590A1 (en) * 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
US20060240125A1 (en) * 2005-04-21 2006-10-26 Astrup Arne V Composition for affecting weight loss
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1471910A2 (en) * 2002-01-17 2004-11-03 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
DK1539124T3 (en) * 2002-09-05 2018-10-08 Vanderbilt Royalty Sub L P : COMPOSITIONS AND KITS FOR REMOVAL OF BODY SURFACES
EP2422773A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
JP2006514109A (en) * 2002-12-18 2006-04-27 アルゴルクス ファーマスーティカルズ，インク Capsaicinoid administration
MXPA05006670A (en) * 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administration of capsaicinoids.
EA008705B1 (en) * 2003-04-08 2007-06-29 Алгоркс Фармасьютикалз, Инк. Preparation and purification of synthetic capsaicin
US20040224037A1 (en) * 2003-04-28 2004-11-11 Gonzalo Romero-Matos Devastating treatment against hiv/aids with capsaicin
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
BRPI0516912A2 (en) * 2004-11-24 2009-06-23 Algorx Pharmaceuticals Inc capsaicinoid gel formulation and uses
WO2006069451A1 (en) * 2004-12-28 2006-07-06 Mestex Ag Use of resiniferatoxin (rtx) for producing an agent for treating joint pains and method for applying said agent
EP1871179B1 (en) * 2005-01-28 2018-06-06 Archer Daniels Midland Company Animal feed compositions capable of reducing the incidence of fescue toxicosis in mammals
PT1865941E (en) * 2005-04-01 2011-01-05 Neurogesx Inc Oils of capsaicinoids and methods of making and using the same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US20070209599A1 (en) * 2006-03-10 2007-09-13 Archer-Daniels-Midland Company Methods and compositions for increased productivity in animals
JP5457830B2 (en) * 2006-04-03 2014-04-02 オディディ，イサ Controlled release delivery device comprising an organosol coating
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
KR20140079441A (en) 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 Pharmaceutical compositions
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
WO2008109026A1 (en) * 2007-03-05 2008-09-12 Mt Cook Pharma Pharmaceutical compositions for the localized treatment of neurogenic dysfunction
US8165669B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8989858B2 (en) * 2007-12-05 2015-03-24 The Invention Science Fund I, Llc Implant system for chemical modulation of neural activity
US8195287B2 (en) 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8180446B2 (en) * 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US20090149799A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for chemical modulation of neural activity
US8165668B2 (en) 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8170659B2 (en) * 2007-12-05 2012-05-01 The Invention Science Fund I, Llc Method for thermal modulation of neural activity
US8233976B2 (en) 2007-12-05 2012-07-31 The Invention Science Fund I, Llc System for transdermal chemical modulation of neural activity
US8170658B2 (en) * 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US8987328B2 (en) 2008-10-30 2015-03-24 Trinity Laboratories, Inc. Esters of capsaicinoids as dietary supplements
US20100303932A1 (en) * 2009-05-28 2010-12-02 Baskaran Thyagarajan Method for Attenuating the Effects of Botulinum Toxin
US20110135627A1 (en) * 2009-10-07 2011-06-09 The Inflasoothe Group, Inc. Pain relief composition, system and method
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2012012319A1 (en) 2010-07-19 2012-01-26 3M Innovative Properties Company Hand tool with replaceable knife cartridge
PL2629610T3 (en) 2010-07-27 2018-02-28 Flex Pharma, Inc. Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
PL2826467T3 (en) 2010-12-22 2018-01-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (en) 2010-12-23 2016-09-05 Purdue Pharma Lp Solid oral dosage forms resistant to alterations
AP2015008579A0 (en) 2013-02-05 2015-07-31 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US11253493B2 (en) 2017-01-23 2022-02-22 Cliff-Cartwright Corporation Compositions and methods affecting exercise performance
US11707437B2 (en) 2019-07-12 2023-07-25 Board Of Trustees Of Southern Illinois University Topical formulations with resiniferatoxin nanoparticles and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2902506A1 (en) * 1979-01-23 1980-07-24 Deutsches Krebsforsch USE OF DITERPENAL ALCOHOLS AND DERIVATIVES THEREOF AS AN ANTINEOPLASTIC AGENT, OR ONLY LITTLE IRRITATING AND / OR PROMOVING
US4536404A (en) * 1983-06-16 1985-08-20 Dermatological Enterprises, Ltd. Method and composition for treating post-herpetic neuralgia
AU5744490A (en) * 1989-05-15 1990-12-18 Afferon Corporation Composition and method for neural desensitization

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 93, No. 11, issued 15 September 1980 (Columbus, Ohio, USA, WILIAMSON et al, "The effect of daphnane esters on platelet aggregation and erythema of the mouse ear", J. Pharm. Pharmacol. Pharm. London, 1980, 32(5) 373-4. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020867A1 (en) * 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists

Also Published As

Publication number Publication date
DE68910834T2 (en) 1994-03-17
CA2001194C (en) 1995-12-05
DE68910834D1 (en) 1993-12-23
AU4624189A (en) 1990-05-14
EP0439549A4 (en) 1991-12-04
AU619930B2 (en) 1992-02-06
CA2001194A1 (en) 1990-04-24
EP0439549A1 (en) 1991-08-07
JPH03504387A (en) 1991-09-26
US4939149A (en) 1990-07-03
EP0439549B1 (en) 1993-11-18
JPH0729919B2 (en) 1995-04-05
IL92082A0 (en) 1990-07-12
US5290816A (en) 1994-03-01

Similar Documents

Publication Publication Date Title
US4939149A (en) Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization
Szallasi et al. Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper
Monsereenusorn et al. Capsaicin—a literature survey
AU644363B2 (en) New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
Habib et al. Evaluation of anti-nociceptive, anti-inflammatory and antipyretic activities of Artemisia scoparia hydromethanolic extract
Hayman et al. Capsaicin: A review of its pharmacology and clinical applications
Esposito et al. Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α
CA2289119C (en) Methods for treating inflammation and inflammatory diseases using padprt inhibitors
JP2004529907A (en) How to treat restenosis
Latha et al. Inhibition of chemical carcinogenesis by Psoralea corylifolia seeds
Miller et al. Inhibition of neurogenic inflammation by the Amazonian herbal medicine sangre de grado
Jiang et al. Inhibition of two-stage skin carcinogenesis as well as complete skin carcinogenesis by oral administration of TMK688, a potent lipoxygenase inhibitor
US5420162A (en) Phorbol ester pharmaceutical compositions and their use for treating inflammation
AU2011351948B2 (en) Topical nitrone spin trap compositions for psoriasis
Szallasi et al. Neurogenic component of phorbol ester-induced mouse skin inflammation
US3036955A (en) Analgesic 5-lower alkyl-2-amino thiazoles
AU2011351948A1 (en) Topical nitrone spin trap compositions for psoriasis
DE69923864T2 (en) EXTRACTS FROM SELLERIESAMEN FOR THE PREVENTION AND TREATMENT OF INFLAMMATIONS AND GASTROINTESTINAL IRRITATIONS
Krishnaveni et al. Antiinflammatory and analgesic actions of 4’, 5, 6-trihydroxy-3’7-dimethoxy flavone-from Vicoa indica DC
Verbeuren et al. Regulation of adhesion molecules: a new target for the treatment of chronic venous insufficiency
CA2111774A1 (en) Use of alkanolamines
Skala et al. Effect of 6-hydroxydopamine and α-methyltyrosine on brown adipose tissue of infant rats
Waheed et al. Capsaicin
JPS61103826A (en) Anti-inflammatory agent
JPH072676A (en) Pharmaceutical preparation and/or cosmetic preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989912770

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989912770

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989912770

Country of ref document: EP